The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer

Phase 2 Completed 94 enrolled University College, London Cancer Research UK · collab Oxford BioMedica · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this trial is to assess the effectiveness of TroVax® compared to placebo in extending the time to progression in patients with asymptomatic relapsed platinum resistant ovarian, fallopian tube or primary peritoneal cancer.The trial will also look at overall survival times and quality of life.

Timeline

Start: 2013-11
Primary completion: 2019-04-19
Completion: 2019-04-19

Outcome

Missed primary endpoint

paper MVA-5T4 vaccination in patients with asymptomatic relapse was well-tolerated but did not improve the progression rate at 25 weeks. PMID 38760075 ↗

Publications

Michael A, Wilson W, Sunshine S, Annels N, Harrop R, Blount D, Pandha H, Lord R, Ngai Y, Nicum S, Stylianou L, Gwyther S, McNeish IA, Hackshaw A, Ledermann J. A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC). Int J Gynecol Cancer. 2024 Aug 5;34(8):1225-1231. doi: 10.1136/ijgc-2023-005200.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TroVax	Vaccine	1e+09 unknown	Intramuscular